Galena Biopharma Inc. is all but hat in hand, launching a registered direct offering July 8 to raise additional funding as it made public its intention to have a third party review the operational information from a recently halted Phase III trial of its NeuVax to determine what possible factors, other than efficacy, caused the breast cancer vaccine candidate to fail a futility analysis.
The San Ramon, Calif.-based company reported June 29 that based on an interim analysis, the independent data monitoring committee for...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)